BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lindsay JO, Chipperfield R, Giles A, Wheeler C, Orchard T; INDIGO study investigators. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2013;38:52-61. [PMID: 23701393 DOI: 10.1111/apt.12339] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Miot J, Smith S, Bhimsan N. Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective. Int J Clin Pharm 2016;38:880-7. [PMID: 27118462 DOI: 10.1007/s11096-016-0304-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
3 Eberhardson M, Söderling JK, Neovius M, Cars T, Myrelid P, Ludvigsson JF, Askling J, Ekbom A, Olén O. Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther 2017;46:589-98. [DOI: 10.1111/apt.14224] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
4 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349-1362. [PMID: 24749763 DOI: 10.1111/apt.12749] [Cited by in Crossref: 107] [Cited by in F6Publishing: 98] [Article Influence: 13.4] [Reference Citation Analysis]
5 Einarson TR, Bereza BG, Ying Lee X, Lelli F. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Current Medical Research and Opinion 2017;33:1433-49. [DOI: 10.1080/03007995.2017.1335001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hossain A, Lördal M, Olsson AE, Storlåhls A, Aleman S, Eberhardson M, Befrits R. Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease. Scand J Gastroenterol 2020;55:178-83. [PMID: 32052663 DOI: 10.1080/00365521.2020.1722738] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
8 Marcelino MY, Fuoco NL, Quaglio AEV, de Camargo Bittencourt RA, Garms BC, da Motta Conceição TH, Stasi LCD, Ribeiro-paes JT. Cell therapy in experimental model of inflammatory bowel disease. Journal of Coloproctology 2021;35:020-7. [DOI: 10.1016/j.jcol.2014.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
9 George LA, Gadani A, Cross RK, Jambaulikar G, Ghazi LJ. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease. Dig Dis Sci 2015;60:3424-30. [PMID: 26115749 DOI: 10.1007/s10620-015-3763-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Norton C, Czuber-Dochan W, Artom M, Sweeney L, Hart A. Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:115-125. [PMID: 28470846 DOI: 10.1111/apt.14108] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
11 Mandel MD, Balint A, Golovics PA, Vegh Z, Mohas A, Szilagyi B, Szabo A, Kurti Z, Kiss LS, Lovasz BD. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres. Dig Liver Dis. 2014;46:985-990. [PMID: 25156871 DOI: 10.1016/j.dld.2014.07.168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
12 Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. J Can Assoc Gastroenterol. 2019;2:S17-S33. [PMID: 31294382 DOI: 10.1093/jcag/gwy055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
13 Lelli F, Nuhoho S, Lee XY, Xu W. Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. Clin Exp Gastroenterol 2016;9:311-23. [PMID: 27785086 DOI: 10.2147/CEG.S109696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Lam WL, Saunders J, Kelly C, Gaya D, Jafferbhoy H, Macdonald JC, Seenan JP, Mowat C, Naismith G, Potts LF, Sutherland DI, Watts D, Arnott I, Bain G, Jones G, Lees CW. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. J Gastroenterol Hepatol 2021;36:2067-75. [PMID: 33381875 DOI: 10.1111/jgh.15390] [Reference Citation Analysis]